Association of dopamine-related gene alleles, smoking behavior and decline in FEV1 in subjects with COPD: Findings from the Lung Health Study

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 9, Issue 6, 2012, Pages 620-628

  Tashkin, Donald P ^a   Rabinoff, Michael ^b,c   Noble, Ernest P ^b   Ritchie, Terry L ^b   Simmons, Michael S ^a   Connett, John ^d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c KAISER PERMANENTE MEDICAL CENTER   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

COPD; Ddecline in FEV1; Ddopamine; Ggene alleles; Ssmoking behavior

Indexed keywords

COTININE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; ISOPRENALINE; METHACHOLINE;

ADULT; AIRWAY OBSTRUCTION; ALLELE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE COURSE; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC MARKER; GENOTYPE; HUMAN; INTERVENTION STUDY; LEUKOCYTE; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SMOKING; SMOKING CESSATION; SMOKING CESSATION PROGRAM;

ADULT; DISEASE PROGRESSION; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; GENETIC MARKERS; GENOTYPE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RECEPTORS, DOPAMINE D2; SEVERITY OF ILLNESS INDEX; SMOKING; SMOKING CESSATION; TREATMENT OUTCOME;

EID: 84871502639     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2012.712167     Document Type: Article

References (45)

1. Davis RM, Novotny TE. The epidemiology of cigarette smoking and its impact on chronic obstructive pulmonary disease. Am Rev Respir Dis 1989; 140: (3 Pt 2):S82-84.
2. Fletcher C, Peto R. The natural history of chronic airfl ow obstruction. Br Med J 1977; 1(6077):1645-1648.
3. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1 - The lung health study. JAMA 1994; 272: 1497-1505.
4. Scanlon PD, Connett JE, Waller L, et al. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: The Lung Health Study. Am J Respir Crit Care Med 2000; 161:381-390.
5. Pride NB. Smoking cessation: Effects on symptoms, spirometry and future trends in COPD. Thorax 2001; 56 (Suppl 2): ii7-10.
6. Jiménez-Ruiz CA, Masa F, Miravitlles M, et al. Smoking characteristics: diff erences in attitudes and dependence between healthy smokers and smokers with COPD. Chest 2001; 119:1365-1370.
7. Buist AS, Connett JE, Miller RD, et al. Chronic Obstructive Pulmonary Disease Early Intervention Trial (Lung Health Study): Baseline characteristics of randomized participants. Chest 1993; 103:1863-1872.
8. Noble EP, St. Jeor ST, Ritchie T, et al. D2 dopamine receptor gene and cigarette smoking: A reward gene? MedicalHypotheses 1994; 42:257-260.
9. Noble EP. D2 dopamine receptor gene in psychiatric and neurologic disorders and its phenotypes: a review. Am J Med Genet (Neuropsychiatric Genetics) 2003; 116:103-125.
10. Lerman C, Caporaso NE, Audrain J, et al. Evidence suggesting the role of specifi c genetic factors in cigarette smoking. Health Psychol 1999; 18:14-20.
11. Sabol SZ, Nelson ML, Fisher C, et al. A genetic association for cigarette smoking behavior. Health Psychol 1999; 18:7-13.
12. Old JM, Davies KE. Prenatal diagnosis of Duchenne muscular dystrophy by DNA analysis. J Med Genet, 1986; 23: 556-559.
13. Saiki RK, Gelfand DH, Stoff er S, et al. Primer-directed enzymatic amplifi cation of DNA with a thermostable DNA polymerase. Science 1988; 239:487-491.
14. Noble EP, Noble RE, Ritchie T, et al. D2 dopamine receptor gene and obesity. Int J Eat Disord 1994;15:205-17.
15. Vandenbergh DJ, Persico Am, Hawkins AL, et al. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992; 14:1104-1106.
16. Crapo RD, Morris AH, Gardner RM. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981; 123:659-664.
17. Tashkin DP, Altose MD, Connett JE, et al. Methacholine reactivity predicts changes in lung function over time in smokers with early COPD. Am J Respir Crit Care Med 1996; 153:1802-1811.
18. O'Connor GT, Sparrow D, Weiss ST. A prospective longitudinal study of methacholine airway responsiveness as a predictor of pulmonary function decline: The Normative Aging Study. Am J Respir Crit Care Med 1995; 152:87-92.
19. Connett JE, Murray RP, Buist AS, et al. Changes in smoking status aff ect women more than men: Results of the Lung Health Study. Am J Epidem 2003; 157:973-979.
20. Laird NM, Ware JH. Random Effects models for longitudinal data. Biometrics 1982; 32:963-974.
21. Hogg JC, Chu F, Utokaparch S, et al. The nature of small airway obstruction in chronic obstructive pulmonary disease. N Engl J Med; 2004; 350:2645-2653.
22. Silverman EK, Spira A, Pare PD. Genetics and genomics of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2009; 6:539-542.
23. Hersh CP. Pharmacogenetics of chronic obstructive pulmonary disease: challenges and opportunities. Pharmacogenomics 2010; 11:237-247.
24. Takabatake N, Toriyama S, Igarashi A, et al. A novel polymorphism in CDC6 is associated with the decline in lung function of ex-smokers in COPD. Biochem Biophys Res Commun 2009; 38:554-559.
25. Missale C, Nash SR, Robinson SW. Dopamine receptors: from structure to function. Physiol Rev 1998; 78:189-225.
26. Bruzzone P, D'Andrea V, Motta C, et al. Occurrence of dopaminergic (D(2)) receptros within the rabbit pulmonary circulation. Pulm Pharmacol Ther 2001; 15:393-398.
27. Jackson DM, Simpson WT. The Effect of dopamine on the rapidly adapting receptors in the dog lung. Pulm Pharmacol Ther 2000; 13:39-42.
28. Xie GX, Jones K, Peroutka SJ, et al. Detection of mRNAs and alternatively spliced transcripts of dopamine receptors in rat peripheral sensory and sympathetic ganglia. Brain Res 1998; 785:129-135.
29. Bierell MA, Crispino N, Hele DJ, et al. Effect of dopamine receptor agonists on sensory nerve activity: possible therapeutic targets for the treatment of asthma and COPD. Br J Pharmacol 2002; 136:620-628.
30. Bonnert RV, Brown RC, Chapman D, et al. Dual D2-receptor and beta2-adrenoceptor agonists for the treatment of airway diseases. 1. Discovery and biological evaluation of some 7-(2-aminoethy)-4-hydroxybenzothiasol-2(3H)- one analogues. J Med Chem 1998; 41:4915-4917.
31. Chen Y, Horne SL, Dosman JA. Increased susceptibility to lung dysfunction in female smokers. Am Rev Respir Dis 1991; 143:1224-1230.
32. Dransfi eld MT, Washko GR, Foreman MG, et al. Gender diff erences in the severity of CT emphysema in COPD. Chest 2007; 132:464-470.
33. Martinez FJ, Curtis JL, Sciurba F, et al. Sex diff erences in severe pulmonary emphysema. Am J Respir Crit Care Med 2007; 176; 243-252.
34. Limosin, F, Gorwood P, Loze J-Y, Dubertet C, Gouya L, Deybach J-C, Adès J. Male limited association of the dopamine D2 gene Taq1A polymorphism and alcohol dependence. Am J Med Genet 2002; 112: 343-346.
35. Lopez-Castroman J, Vaquero-Lorenzo C, Mercedez Perez- Rodriguez M, et al. Gender Effect on association between DRD2 polymorphism and substance dependence in a Spanish sample. Drug Alcohol Depend 2009; 101: 210-212.
36. Munafo MR, Timpson NJ, David SP, et al. Association of the DRD2 geneTaq1A polymorphism and smoking behavior: a meta-analysis and new data. Nicotine Tobacco Res 2009; 11: 64-76.
37. Lin J-J, Yueh K-C, Chang D-C, et al. The homozygote 10-copy genotype of variable number tandem repeat dopamine transporter gene may confer protection against Parkinson's disease for male, but not to female patients. J Neurol Sci 2003; 209: 87
38. Kaasinen V, Nagren K, Hietala J, et al. Sex diff erences in extrastriatal dopamine D2 - like receptors in the human brain. Am J Psych 2001; 158: 308-311.
39. Farde L, Hall H, Pauli S, et al. Variability in D2 - dopamine receptor density and affi nity; a PET study with (C) raclopride in man. Synapse 1995; 20:200-208.
40. Pohjalainen T, Rinne J, Nagren K, et al. Sex diff erences in striatal dopamine D2 receptor binding characteristics in vivo. Am J Psych 1998; 155:768-773.
41. Noble EP, Blum K, Ritchie T, et al. Allelic association of the D2 dopamine receptor gene with receptor binding characteristics in alcoholism. Arch Gen Psych 1991; 48:648-654.
42. Thompson J, Thomas N, Singleton A, et al. D2 dopamine receptor gene (DRD2) Taq1A polymorphism: reduced dopamine D2 receptor binding in the human striatum associated with the A1 allele. Pharmacogenetics 1997; 7:479-484.
43. Pohjalainen T, Rinne JO, Nagren K, et al. The A1 allele of the human D2 dopamine receptor gene predicts low D2 receptor availability in healthy volunteers. Mol Psych 1998; 3:256-260.
44. Jonsson EG, Nothen MM, Grunhage F, et al. Polymorphisms in the dopamine D2 receptor gene and their relationships to striatal dopamine receptor density of healthy volunteers. Mol Psych 1999; 4:290-296.
45. Ponce G, Perez-Gonzalez R, Aragues M, et al. The ANKK1 Kinase Gene and psychiatric disorders. Neurotox Res 2009; 16:50-59.